Acorda Therapeutics Cdt Stock
Pros and Cons of Acorda Therapeutics Cdt in the next few years
Pros
?
S********** s********
?
W********* I********* f** t** n*** y****
?
M***** P*******
Cons
?
C******** o* t** e**********
?
G***** c******* t* c**********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Acorda Therapeutics Cdt vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Acorda Therapeutics Cdt | - | - | - | - | - | - | - |
Ardelyx Inc. | 0.440% | -8.479% | 12.586% | 75.426% | 24.740% | 28.750% | - |
Evolus Inc | - | -4.132% | 4.505% | 26.087% | 28.177% | 57.823% | - |
Salarius Pharmaceuticals Inc. | -2.360% | 2.475% | -4.167% | -62.018% | -25.405% | -98.319% | -99.992% |
Comments
Acorda Therapeutics, Inc. (NASDAQ: ACOR) is now covered by analysts at StockNews.com. They set a "buy" rating on the stock.
Show more
Ratings data for ACOR provided by MarketBeat
Acorda Therapeutics, Inc. (NASDAQ: ACOR) is now covered by analysts at StockNews.com. They set a "buy" rating on the stock.
Show more
Ratings data for ACOR provided by MarketBeat
Acorda Therapeutics, Inc. (NASDAQ: ACOR) is now covered by analysts at StockNews.com. They set a "buy" rating on the stock.
Show more
Ratings data for ACOR provided by MarketBeat